SEC Form 4 · accession 0001209191-18-054531

Ultragenyx Pharmaceutical Inc. · RARE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

William Aliski

Director

Period of report

Feb 5, 2014

Accepted (ET)

Oct 9, 2018 · 4:36 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001515673

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Feb 5, 2014	C	84,970	—	A	121,900	I	By trust
Common Stock^F2	May 12, 2015	S	10,500	$68.65	D	111,400	I	By trust
Common Stock^F2	May 27, 2015	S	2,000	$85.94	D	109,400	I	By trust
Common Stock^F2	Jul 27, 2015	S	400	$122.58	D	109,000	I	By trust
Common Stocki^F2	Apr 19, 2018	S	650	$53.97	D	108,350	I	By trust
Common Stock^F2	Oct 8, 2018	S	6,000	$73.38	D	102,350	I	By trust
Common Stock	holding	—	—		—	72,610	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F2,F4,F5	—	Feb 5, 2014	C	266,343	D	—	—	Common Stock	84,970	0	I

Explanation of responses

F1The number of shares of Common Stock reported reflects the automatic conversion of shares of Series A Preferred Stock into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering.
F2These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust.
F3The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person's trust pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F4Each share of Series A Convertible Preferred Stock was convertible into Common Stock at any time and automatically converted into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.
F5The number of underlying shares of Common Stock reported in Column 7 reflects the automatic conversion of shares of Series A Preferred Stock into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering.

Remarks

In addition to reporting a current indirect transaction by a trust holding shares for the benefit of the reporting person's spouse and children, this Form 4 also reports previously unreported historical transactions by the trust.